DARE
Daré Bioscience, Inc.
There isn't enough reported data to score DARE yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
DARE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Weak | |
| Unavailable |
DARE's profitability and cash flow are currently weak. There isn't enough data to rate its revenue and balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
DARE PE Valuation
DARE has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
DARE Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect DARE's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
DARE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$0.80 | +$1.35 |
| Q1 2026 | -$1.05 | -$0.87 |
| Q4 2025 | -$1.34 | -$0.82 |
| Q3 2025 | -$1.88 | -$1.17 |
| Q2 2025 | -$2.15 | -$0.91 |
| Q1 2025 | -$0.18 | +$3.78 |
| Q4 2024 | -$0.52 | +$3.68 |
| Q3 2024 | -$0.71 | +$4.93 |
DARE is still losing money, but far less than before: $0.80 per share over the past year, against $11.64 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over DARE on earnings quality, reporting a profit while its opponent remains loss making.
DARE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q1 2026 | $152.5K | +500% |
| Q3 2025 | $2.3K | -95% |
| Q1 2025 | $25.4K | +173% |
| Q3 2024 | $41.7K | -96% |
DARE's revenue has slid since its 2022 peak: $187,546 last quarter, down 986% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -1583% | N/A |
| Q1 2026 | -1967% | +16050 points |
| Q4 2025 | -144% | N/A |
| Q3 2025 | -162341% | -151112 points |
| Q1 2025 | -18017% | +46727 points |
| Q3 2024 | -11229% | -10389 points |
| Q2 2024 | -32799% | N/A |
| Q1 2024 | -64744% | N/A |
DARE's operating margin was −1583% last quarter, up 16434 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over DARE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over DARE on profitability, with a higher operating margin.
DARE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$6.9M | -$1.6M |
| Q1 2026 | -$5.5M | +$107.2K |
| Q4 2025 | $1.2M | -73% |
| Q3 2025 | -$616.8K | +$5M |
| Q2 2025 | -$5.3M | -142% |
| Q1 2025 | -$5.6M | +$1.2M |
| Q4 2024 | $4.7M | +$13.4M |
| Q3 2024 | -$5.6M | +$2.4M |
DARE has burned cash in most quarters: −$12M over the past year, against −$12M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over DARE on cash generation, producing positive trailing cash flow while its opponent burns cash.
DARE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.5% | +367K shares |
| 1 year | +70% | +6.1M shares |
| 3 years | +109% | +7.8M shares |
| 5 years | +466% | +12.3M shares |
DARE has 15M diluted shares, up 70% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | — |
| Q4 2024 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over DARE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
DARE Net Leverage
DARE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
DARE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.6 | Oversold |
DARE's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
DARE PE vs Healthcare Sector
DARE has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
DARE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.72 | 11% below |
| 20 week MA | $1.02 | 37% below |
| 50 week MA | $1.60 | 60% below |
| 100 week MA | $2.11 | 70% below |
| 200 week MA | $4.43 | 86% below |
DARE is in a downtrend: it's below all five of its weekly moving averages, and 86% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over DARE on trend strength, trading above more of its moving averages.
DARE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.84 | $16.9 | +72% |
| 2021 | $16.9 | $24.8 | +47% |
| 2022 | $24.8 | $10.4 | -58% |
| 2023 | $10.4 | $3.71 | -64% |
| 2024 | $3.71 | $3.27 | -12% |
| 2025 | $3.27 | $2.15 | -34% |
| 2026 YTD | $2.15 | $0.64 | -70% |
DARE has finished four years in a row lower, and it's down 70% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over DARE on returns for 2026, with the stronger performance.